186 related articles for article (PubMed ID: 20066413)
21.
Das S; Al-Toubah T; El-Haddad G; Strosberg J
Expert Rev Gastroenterol Hepatol; 2019 Nov; 13(11):1023-1031. PubMed ID: 31652074
[No Abstract] [Full Text] [Related]
22. Treatment with the radiolabeled somatostatin analog [177 Lu-DOTA 0,Tyr3]octreotate: toxicity, efficacy, and survival.
Kwekkeboom DJ; de Herder WW; Kam BL; van Eijck CH; van Essen M; Kooij PP; Feelders RA; van Aken MO; Krenning EP
J Clin Oncol; 2008 May; 26(13):2124-30. PubMed ID: 18445841
[TBL] [Abstract][Full Text] [Related]
23. Overview of results of peptide receptor radionuclide therapy with 3 radiolabeled somatostatin analogs.
Kwekkeboom DJ; Mueller-Brand J; Paganelli G; Anthony LB; Pauwels S; Kvols LK; O'dorisio TM; Valkema R; Bodei L; Chinol M; Maecke HR; Krenning EP
J Nucl Med; 2005 Jan; 46 Suppl 1():62S-6S. PubMed ID: 15653653
[TBL] [Abstract][Full Text] [Related]
24. Quality of life in 265 patients with gastroenteropancreatic or bronchial neuroendocrine tumors treated with [177Lu-DOTA0,Tyr3]octreotate.
Khan S; Krenning EP; van Essen M; Kam BL; Teunissen JJ; Kwekkeboom DJ
J Nucl Med; 2011 Sep; 52(9):1361-8. PubMed ID: 21795361
[TBL] [Abstract][Full Text] [Related]
25. Super-selective hepatic arterial infusions as established technique ('ARETAIEION' Protocol) of [177Lu]DOTA-TATE in inoperable neuroendocrine liver metastases of gastro-entero-pancreatic (GEP) tumors.
Limouris GS; Karfis I; Chatzioannou A; Paphiti MI; Lyra M; Gennatas K; Nikou G; Voros D; Pragulidis GP; Polydorou AA; Gouliamos A
Q J Nucl Med Mol Imaging; 2012 Dec; 56(6):551-8. PubMed ID: 23358409
[TBL] [Abstract][Full Text] [Related]
26. Subacute haematotoxicity after PRRT with (177)Lu-DOTA-octreotate: prognostic factors, incidence and course.
Bergsma H; Konijnenberg MW; Kam BL; Teunissen JJ; Kooij PP; de Herder WW; Franssen GJ; van Eijck CH; Krenning EP; Kwekkeboom DJ
Eur J Nucl Med Mol Imaging; 2016 Mar; 43(3):453-63. PubMed ID: 26419852
[TBL] [Abstract][Full Text] [Related]
27. Persistent Hematologic Dysfunction after Peptide Receptor Radionuclide Therapy with
Bergsma H; van Lom K; Raaijmakers MHGP; Konijnenberg M; Kam BLBLR; Teunissen JJM; de Herder WW; Krenning EP; Kwekkeboom DJ
J Nucl Med; 2018 Mar; 59(3):452-458. PubMed ID: 28775205
[TBL] [Abstract][Full Text] [Related]
28. Up-regulation of somatostatin receptor density on rat CA20948 tumors escaped from low dose [177Lu-DOTA0,Tyr3]octreotate therapy.
Melis M; Forrer F; Capello A; Bijster M; Bernard BF; Reubi JC; Krenning EP; De Jong M
Q J Nucl Med Mol Imaging; 2007 Dec; 51(4):324-33. PubMed ID: 17923824
[TBL] [Abstract][Full Text] [Related]
29. Efficacy and safety of 90Y-DOTATATE therapy in neuroendocrine tumours.
Sowa-Staszczak A; Pach D; Kunikowska J; Krolicki L; Stefanska A; Tomaszuk M; Buziak-Bereza M; Mikolajczak R; Matyja M; Gilis-Januszewska A; Jabrocka-Hybel A; Trofimiuk M; Hubalewska-Dydejczyk A
Endokrynol Pol; 2011; 62(5):392-400. PubMed ID: 22069099
[TBL] [Abstract][Full Text] [Related]
30. Effect of calculation method on kidney dosimetry in
Heikkonen J; Mäenpää H; Hippeläinen E; Reijonen V; Tenhunen M
Acta Oncol; 2016; 55(9-10):1069-1076. PubMed ID: 27219529
[TBL] [Abstract][Full Text] [Related]
31. Predictors of long-term outcome in patients with well-differentiated gastroenteropancreatic neuroendocrine tumors after peptide receptor radionuclide therapy with 177Lu-octreotate.
Ezziddin S; Attassi M; Yong-Hing CJ; Ahmadzadehfar H; Willinek W; Grünwald F; Guhlke S; Biersack HJ; Sabet A
J Nucl Med; 2014 Feb; 55(2):183-90. PubMed ID: 24434296
[TBL] [Abstract][Full Text] [Related]
32. Comparison of 111In-[DTPA0]Octreotide Versus Non Carrier Added 177Lu- [DOTA0,Tyr3]-Octreotate Efficacy in Patients With GEP-NET Treated Intra-arterially for Liver Metastases.
Limouris GS; Poulantzas V; Trompoukis N; Karfis I; Chondrogiannis S; Triantafyllou N; Gennimata V; Moulopoulou LE; Patsouris E; Nikou G; Michalaki V; Fragulidis G; Paphiti M; McCready RV; Colletti PM; Cook GJ; Rubello D
Clin Nucl Med; 2016 Mar; 41(3):194-200. PubMed ID: 26673241
[TBL] [Abstract][Full Text] [Related]
33. Dose response of pancreatic neuroendocrine tumors treated with peptide receptor radionuclide therapy using 177Lu-DOTATATE.
Ilan E; Sandström M; Wassberg C; Sundin A; Garske-Román U; Eriksson B; Granberg D; Lubberink M
J Nucl Med; 2015 Feb; 56(2):177-82. PubMed ID: 25593115
[TBL] [Abstract][Full Text] [Related]
34. Renal and hematological toxicity in patients of neuroendocrine tumors after peptide receptor radionuclide therapy with 177Lu-DOTATATE.
Gupta SK; Singla S; Bal C
Cancer Biother Radiopharm; 2012 Nov; 27(9):593-9. PubMed ID: 23009580
[TBL] [Abstract][Full Text] [Related]
35. Salvage PRRT with
Rudisile S; Gosewisch A; Wenter V; Unterrainer M; Böning G; Gildehaus FJ; Fendler WP; Auernhammer CJ; Spitzweg C; Bartenstein P; Todica A; Ilhan H
BMC Cancer; 2019 Aug; 19(1):788. PubMed ID: 31395036
[TBL] [Abstract][Full Text] [Related]
36. High clinical and morphologic response using
Kong G; Callahan J; Hofman MS; Pattison DA; Akhurst T; Michael M; Eu P; Hicks RJ
Eur J Nucl Med Mol Imaging; 2017 Mar; 44(3):476-489. PubMed ID: 27678267
[TBL] [Abstract][Full Text] [Related]
37. Bone marrow dosimetry in peptide receptor radionuclide therapy with [177Lu-DOTA(0),Tyr(3)]octreotate.
Forrer F; Krenning EP; Kooij PP; Bernard BF; Konijnenberg M; Bakker WH; Teunissen JJ; de Jong M; van Lom K; de Herder WW; Kwekkeboom DJ
Eur J Nucl Med Mol Imaging; 2009 Jul; 36(7):1138-46. PubMed ID: 19247653
[TBL] [Abstract][Full Text] [Related]
38. Peptide receptor radionuclide therapy with 177Lu-DOTA-octreotate: dosimetry, nephrotoxicity, and the effect of hematological toxicity on survival.
Löser A; Schwarzenböck SM; Heuschkel M; Willenberg HS; Krause BJ; Kurth J
Nucl Med Commun; 2018 Mar; 39(3):236-246. PubMed ID: 29315138
[TBL] [Abstract][Full Text] [Related]
39. Feasibility and utility of re-treatment with (177)Lu-DOTATATE in GEP-NENs relapsed after treatment with (90)Y-DOTATOC.
Severi S; Sansovini M; Ianniello A; Bodei L; Nicolini S; Ibrahim T; Di Iorio V; D'Errico V; Caroli P; Monti M; Paganelli G
Eur J Nucl Med Mol Imaging; 2015 Dec; 42(13):1955-63. PubMed ID: 26112388
[TBL] [Abstract][Full Text] [Related]
40. 177Lu-[DOTA0,Tyr3] octreotate therapy in patients with disseminated neuroendocrine tumors: Analysis of dosimetry with impact on future therapeutic strategy.
Garkavij M; Nickel M; Sjögreen-Gleisner K; Ljungberg M; Ohlsson T; Wingårdh K; Strand SE; Tennvall J
Cancer; 2010 Feb; 116(4 Suppl):1084-92. PubMed ID: 20127957
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
